|
|
 |
|
Viewing report
|
|
|
|
Strategic Analysis of the World Plant Molecular Farming Market
Frost & Sullivan, Dec 2004
Recombinant Plants to Alleviate Production Issues in Plant Molecular Farming
The demand for biopharmaceuticals is increasing, but little progress is being made to reduce production costs or increase manufacturing capacity. There are insufficient facilities to cope with the demand for products and new leads in drug discovery. The use of recombinant plants as factories to express recombinant proteins has the potential to alleviate this bottleneck. The production platforms and technologies that enable this are now in place and the onus is squarely on product development to commercially introduce therapeutics, and several companies have attracted venture capital sponsorship, and they are likely to be in a position to achieve this within the next two years.
This strategic analysis service provides an overview of and outlook for the world plant molecular farming (biofarming) market. The study provides information on the world industry dynamics with a particular focus on North America and Europe as major centers of activity in this sector. It also offers strategic recommendations that enable companies to align their positioning strategies to benefit from the changing markets and obtain maximum return on investment.
Transgenic Plants Have the Potential to Improve Biopharmaceutical Production Efficiency
Biopharmaceutical manufacturers’ concerns about production capacity can be eased by investing in new manufacturing technologies and methods such as using transgenic plants as factories to produce biopharmaceuticals. The cost of production can be significantly reduced by producing larger volumes, and eliminating the need for capital investment in fermentation systems, says the analyst of this research.
Using microscopic plants such as lemna or moss in bioreactors have the potential to eliminate containment problems and improve turnover times by simplifying recombination procedures.
Drug Discovery Market Governed by Regulatory Affairs and Public Perception
Currently, there are no biopharmaceutical products manufactured using plant molecular farming in the market, with the first products anticipated to reach the market around 2005-06. However, the U.S. market could be worth $2.20 billion in 2011, as this emerging sector rapidly gathers pace as public perception and the regulatory climate improve. Growth is likely to occur fastest between 2008 and 2010 as more products enter the market and receive regulatory approval.
The gradual relaxation of the unofficial moratorium on transgenic crops in Europe is a good indication that the public and regulatory perception toward transgenic crops is improving, and this trend is expected to drive the market, notes the analyst.
|
|
|
|
